Lisa Masucci, John Kuruvilla, Beate Sander, Anca Prica, William W L Wong, Kelvin K W Chan
{"title":"在加拿大，使用嵌合抗原受体t细胞治疗的患者的实际医疗保健费用。","authors":"Lisa Masucci, John Kuruvilla, Beate Sander, Anca Prica, William W L Wong, Kelvin K W Chan","doi":"10.1080/10428194.2025.2518440","DOIUrl":null,"url":null,"abstract":"<p><p>Chimeric antigen receptor T-cell (CAR-T) therapy is a practice changing high-cost therapy; however, little is known about the real-world cost of CAR-T. We estimated the acute healthcare costs associated with CAR-T for patients with r/r DLBCL. We performed a retrospective cohort study of patients who received CAR-T between 1 January 2020 and 31 August 2021 at Princess Margaret Cancer Center, Toronto, Ontario. Costs were divided into distinct costing phases. Mean total costs per phase and by service category were calculated. Fifty-three patients received CAR-T. The mean age was 61 years and the majority were male (60%). The total mean costs per patient were: C$11,180 (95% CI: $7712-14,649) for the pretreatment phase (30 days), C$511,983 (average product cost C$473,127) (95% CI: $504,472-520,666) for the treatment phase, and C$41,620 (95% CI: $29,935-52,933) for the post-treatment phase (100 days). This cost information may inform cost-effectiveness analyses for CAR-T as well as reimbursement decisions.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-9"},"PeriodicalIF":2.2000,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-world healthcare costs for patients treated with chimeric antigen receptor T-cell therapy in Canada.\",\"authors\":\"Lisa Masucci, John Kuruvilla, Beate Sander, Anca Prica, William W L Wong, Kelvin K W Chan\",\"doi\":\"10.1080/10428194.2025.2518440\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Chimeric antigen receptor T-cell (CAR-T) therapy is a practice changing high-cost therapy; however, little is known about the real-world cost of CAR-T. We estimated the acute healthcare costs associated with CAR-T for patients with r/r DLBCL. We performed a retrospective cohort study of patients who received CAR-T between 1 January 2020 and 31 August 2021 at Princess Margaret Cancer Center, Toronto, Ontario. Costs were divided into distinct costing phases. Mean total costs per phase and by service category were calculated. Fifty-three patients received CAR-T. The mean age was 61 years and the majority were male (60%). The total mean costs per patient were: C$11,180 (95% CI: $7712-14,649) for the pretreatment phase (30 days), C$511,983 (average product cost C$473,127) (95% CI: $504,472-520,666) for the treatment phase, and C$41,620 (95% CI: $29,935-52,933) for the post-treatment phase (100 days). This cost information may inform cost-effectiveness analyses for CAR-T as well as reimbursement decisions.</p>\",\"PeriodicalId\":18047,\"journal\":{\"name\":\"Leukemia & Lymphoma\",\"volume\":\" \",\"pages\":\"1-9\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-06-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Leukemia & Lymphoma\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/10428194.2025.2518440\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2025.2518440","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Real-world healthcare costs for patients treated with chimeric antigen receptor T-cell therapy in Canada.
Chimeric antigen receptor T-cell (CAR-T) therapy is a practice changing high-cost therapy; however, little is known about the real-world cost of CAR-T. We estimated the acute healthcare costs associated with CAR-T for patients with r/r DLBCL. We performed a retrospective cohort study of patients who received CAR-T between 1 January 2020 and 31 August 2021 at Princess Margaret Cancer Center, Toronto, Ontario. Costs were divided into distinct costing phases. Mean total costs per phase and by service category were calculated. Fifty-three patients received CAR-T. The mean age was 61 years and the majority were male (60%). The total mean costs per patient were: C$11,180 (95% CI: $7712-14,649) for the pretreatment phase (30 days), C$511,983 (average product cost C$473,127) (95% CI: $504,472-520,666) for the treatment phase, and C$41,620 (95% CI: $29,935-52,933) for the post-treatment phase (100 days). This cost information may inform cost-effectiveness analyses for CAR-T as well as reimbursement decisions.
期刊介绍：
Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
